For the past five years, Derik Fay has spent much of his time on the other side of the table.
Rather than running a single operating company day to day, he has advised Fortune 500 executives on mergers and acquisitions, corporate strategy, growth architecture, and the increasingly difficult question of how to create enterprise value in markets moving faster than traditional organizations can comfortably adapt.
Now, Fay is returning to company building himself.
His next chapter is centered on one of healthcare’s fastest growing categories: GLP 1 medications and the broader ecosystem forming around them.
But the more interesting story may not be that Derik Fay is entering the GLP 1 market. It is how five years spent advising large corporations appear to have changed the way he intends to build inside it.
Instead of approaching the sector like a short term consumer trend, Fay is developing a vertically integrated GLP 1 platform with infrastructure, regulatory discipline, compliance, operational controls, and long term enterprise value considered from the beginning.
That distinction matters.
The extraordinary consumer demand surrounding GLP 1 treatments has attracted an equally extraordinary amount of entrepreneurial activity. New platforms have rushed into telehealth, patient acquisition, pharmacy relationships, fulfillment, wellness programs, and weight management services. In markets moving this quickly, growth can become intoxicating.
Fay appears more interested in what remains after the acceleration slows.
His experience advising established companies on M&A has exposed him to a reality founders sometimes discover too late: the characteristics that make a company grow rapidly are not always the same characteristics that make it valuable to an institutional buyer.
Revenue can attract attention. Infrastructure survives diligence.
Customer acquisition can demonstrate demand. Compliance determines whether that demand is defensible.
A compelling brand may open doors, but buyers eventually examine contracts, governance, regulatory exposure, data, systems, margins, concentration risk, management depth, and the extent to which an organization can continue functioning without being dependent on one personality.
Those lessons appear to sit at the center of Fay’s return to operations.
For him, vertical integration is not simply about controlling more pieces of a supply chain. It is about reducing fragmentation.
Healthcare businesses can become structurally complicated very quickly. Patient acquisition may sit in one company, technology in another, clinical services elsewhere, and fulfillment through outside relationships. Every additional handoff can introduce operational friction, compliance concerns, margin leakage, and inconsistent customer experience.
A vertically integrated model offers the possibility of tighter control across those functions, provided it is built responsibly.
That is where Fay’s recent advisory experience becomes particularly relevant.
Someone entering the market purely as a marketer might ask how quickly a patient funnel can scale.
Someone with years of M&A exposure is more likely to ask what that funnel looks like during diligence three years later.
Are the economics durable?
Are the processes documented?
Is compliance embedded into the organization rather than treated as a legal cleanup exercise?
Does the technology create genuine efficiency?
Is management institutionalized?
Can the company withstand regulatory evolution?
Is the enterprise actually transferable?
Those are very different questions, and they tend to produce very different businesses.
Fay has spent much of his career helping companies think beyond their immediate operating circumstances. His advisory work with large businesses reinforced the importance of building backward from the future transaction rather than scrambling to become transaction ready when an opportunity appears.
In the GLP 1 market, that could prove consequential.
The category is already moving beyond a narrow conversation about weight loss. It is becoming an increasingly sophisticated healthcare ecosystem involving patient management, ongoing clinical oversight, technology, education, logistics, data, adherence, and potentially adjacent wellness services.
That creates opportunity, but it also raises the standard of execution.
A company can capture temporary demand with aggressive marketing.
Building something institutionally credible is harder.
Fay’s approach suggests he is attempting the latter.
His return to the operator’s seat also marks an interesting evolution in his career. He is not returning as the same entrepreneur who previously built businesses from instinct and experience alone. He is returning after years spent observing how some of the world’s largest companies evaluate acquisitions, manage risk, allocate capital, and decide which businesses deserve premium valuations.
That accumulated perspective could fundamentally alter how he approaches growth.
The goal is no longer simply to build a successful company.
It is to construct an enterprise that behaves like a sophisticated company before it is forced to become one.
For entrepreneurs, that may be the most valuable lesson in Fay’s newest venture.
A business should not begin thinking about governance when investors request it.
It should not begin documenting processes when acquisition discussions start.
It should not discover compliance after scale.
And it should not confuse rapid customer growth with durable enterprise value.
Fay’s return comes at an unusually important moment for the GLP 1 industry. The market has attracted enormous attention, but the companies that ultimately endure may be those willing to treat infrastructure as seriously as growth.
After five years advising executives on how businesses are bought, sold, scaled, and scrutinized, Derik Fay is once again building one himself.
This time, he is starting with the ending in mind
